Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

KRRO

Korro Bio Inc.

May 20 • 04:00PM ET

54.60

Dollar change -0.06
Percentage change -0.11	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DWAS AVSC

Index	-	P/E	-	EPS (ttm)	-38.14	Insider Own	48.95%	Shs Outstand	8.02M	Perf Week	8.68%
Market Cap	506.14M	Forward P/E	-	EPS next Y	-8.97	Insider Trans	4.05%	Shs Float	4.73M	Perf Month	-18.19%
Income	-81.19M	PEG	-	EPS next Q	-2.46	Inst Own	54.61%	Short Float	2.62%	Perf Quarter	-2.47%
Sales	0.00M	P/S	-	EPS this Y	83.22%	Inst Trans	-28.25%	Short Ratio	3.29	Perf Half Y	33.82%
Book/sh	18.87	P/B	2.89	EPS next Y	-0.76%	ROA	-54.22%	Short Interest	0.12M	Perf Year	467.13%
Cash/sh	15.36	P/C	3.56	EPS next 5Y	-	ROE	-79.36%	52W Range	4.57 - 97.91	Perf YTD	13.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.67%	ROI	-43.64%	52W High	-44.23%	Beta	3.93
Dividend TTM	-	Quick Ratio	13.18	Sales past 5Y	-26.84%	Gross Margin	-	52W Low	1093.44%	ATR (14)	4.61
Dividend Ex-Date	-	Current Ratio	13.18	EPS Y/Y TTM	65.47%	Oper. Margin	0.00%	RSI (14)	43.69	Volatility	6.24% 8.38%
Employees	101	Debt/Eq	0.24	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	126.25
Option/Short	No / Yes	LT Debt/Eq	0.23	EPS Q/Q	91.18%	Payout	-	Rel Volume	1.00	Prev Close	54.66
Sales Surprise	-	EPS Surprise	-2.40%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	37.73K	Price	54.60
SMA20	-4.51%	SMA50	-16.38%	SMA200	35.95%	Trades		Volume	37,287	Change	-0.11%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-24	Reiterated	H.C. Wainwright	Buy	$100 → $115
Feb-27-24	Initiated	BMO Capital Markets	Outperform	$120
Dec-04-23	Initiated	H.C. Wainwright	Buy	$100
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$70
Nov-10-23	Initiated	Piper Sandler	Overweight	$180
Feb-15-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-13-23	Downgrade	Cowen	Outperform → Market Perform
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$12 → $9
Jan-27-21	Upgrade	JP Morgan	Neutral → Overweight	$56
Dec-22-20	Initiated	B. Riley Securities	Buy	$79
Jul-14-20	Initiated	Oppenheimer	Outperform	$36
May-18-20	Downgrade	JP Morgan	Overweight → Neutral	$27
Oct-28-19	Initiated	JP Morgan	Overweight	$25
Oct-28-19	Initiated	Goldman	Buy	$30
Oct-28-19	Initiated	Cowen	Outperform

Show Previous Ratings

May-20-24 02:30PM	Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference (GlobeNewswire)
May-14-24 10:55PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:01PM	Loading…
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
04:01PM	Loading…
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire)
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
07:30AM	Loading…
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)
Apr-08-22 05:00PM	Frequency Exchange Corp. Virtually Closes the Market (PR Newswire) -8.82%
Mar-15-22 07:30AM	Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +15.29%
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks) -13.70%
Feb-28-22 07:30AM	Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences (Business Wire)
Jan-14-22 05:43AM	One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year (Simply Wall St.)
Jan-04-22 07:30AM	Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com) +5.28%
Dec-09-21 01:18PM	Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise (Benzinga)
07:30AM	Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise (Business Wire)
Nov-30-21 05:53AM	Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year ago (Simply Wall St.)
Nov-15-21 12:25PM	Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results (Business Wire)
Nov-09-21 07:30AM	Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis (Business Wire)
Nov-08-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-21 07:30AM	Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program (Business Wire)
Oct-21-21 07:30AM	Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint (Business Wire)
Oct-01-21 08:23AM	Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)? (Simply Wall St.)
Sep-22-21 11:18AM	Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors (Benzinga)
07:30AM	Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points (Business Wire)
Sep-08-21 07:30AM	Frequency Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Aug-30-21 05:10PM	Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG) (ACCESSWIRE)
Aug-12-21 04:06PM	Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm (Newsfile)
08:45AM	Frequency Therapeutics, Inc. (FREQ) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results (Business Wire)
Aug-04-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Aug-02-21 03:05PM	CLASS ACTION UPDATE for JRVR, FREQ and QFIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
02:30PM	Final Deadline Alert: Frequency Therapeutics, Inc. (FREQ) Class Action and Last Chance for Investors to Actively Participate - Bronstein, Gewirtz & Grossman, LLC (ACCESSWIRE)
12:30PM	SHAREHOLDER ALERT: FREQ RKT QFIN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
12:30PM	FINAL DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
11:00AM	FREQ Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (ACCESSWIRE)
10:00AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RKT and BZ (ACCESSWIRE)
09:16AM	FREQ Final Deadline Today: Rosen, National Trial Lawyers, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ (Newsfile)
09:09AM	DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
05:50AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, RLX and DIDI (ACCESSWIRE)
03:27AM	Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Aug-01-21 10:38AM	FREQUENCY DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Frequency To Contact Him Directly To Discuss Their Options (GlobeNewswire)
06:36AM	FREQ FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline Tomorrow in Securities Class Action - FREQ (Newsfile)
Jul-30-21 08:49PM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Frequency Therapeutics, Inc. and Encourages Investors to Contact the Firm (Business Wire)
07:19PM	Frequency Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm (GlobeNewswire)
07:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FREQ (ACCESSWIRE)
05:15PM	FREQ Final Deadline Monday: Rosen, Leading Trial Attorneys, Encourages Frequency Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ (Newsfile)
02:57PM	FREQ LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Frequency Therapeutics, Inc. (Newsfile)
01:30PM	FINAL DEADLINE IMMINENT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
12:40PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, OCGN and BLCT (ACCESSWIRE)
11:30AM	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ) (Business Wire)
11:30AM	CLASS ACTION UPDATE for CCIV, FREQ and RLX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
11:00AM	FREQ INVESTOR ALERT: Shareholder Lawsuit Deadline Approaching (ACCESSWIRE)
10:00AM	SHAREHOLDER ALERT: FREQ RLX DIDI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
10:00AM	FREQ Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (GlobeNewswire)
09:30AM	MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
09:00AM	FREQUENCY THERAPEUTICS SHAREHOLDERS: August 2, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser (ACCESSWIRE)
05:18AM	FREQ ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 2, 2021 in the Class Action Filed on Behalf of Frequency Therapeutics, Inc. Limited Shareholders (Newsfile)
Jul-29-21 08:47PM	Frequency Class Action Reminder (Newsfile)
05:29PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Frequency Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 2, 2021 - FREQ (Newsfile)
04:02PM	MONDAY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - FREQ (PR Newswire)
01:15PM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RLX and OTLY (ACCESSWIRE)
12:30PM	FREQ DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Frequency Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action FREQ (GlobeNewswire)
10:45AM	Lawsuits Filed Against FREQ, DIDI and OTLY - Jakubowitz Law Pursues Shareholders Claims (ACCESSWIRE)
10:00AM	FREQ Monday Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (ACCESSWIRE)
09:24AM	MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
05:27AM	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Frequency Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 2, 2021 - (FREQ) (Newsfile)
Jul-28-21 08:00PM	Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Frequency, Athira, Full Truck, and Coinbase and Encourages Investors to Contact the Firm (GlobeNewswire)
07:25PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FREQ (PR Newswire)

Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mathers Edward T	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
SANDELL SCOTT D	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Makhzoumi Mohamad	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Yang Rick	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Walker Paul Edward	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Florence Anthony A. Jr.	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Chang Carmen	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
BASKETT FOREST	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
New Enterprise Associates 17,	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Atlas Venture Opportunity Fund	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	195,074	Apr 23 05:23 PM
Lucchino David L.	Director	Nov 22 '23	Sale	37.69	1,156	43,573	22,150	Nov 27 08:48 PM
Lucchino David L.	Director	Nov 10 '23	Sale	41.97	968	40,632	23,306	Nov 22 04:05 PM
Lucchino David L.	President and CEO	Aug 18 '23	Sale	0.60	2,865	1,719	636,801	Aug 22 04:19 PM
Mitrano Richard J.	VP Finance & Operations	Aug 18 '23	Sale	0.63	227	143	48,694	Aug 22 04:21 PM
Lucchino David L.	President and CEO	Aug 17 '23	Sale	0.63	2,733	1,722	639,666	Aug 18 08:01 AM
Mitrano Richard J.	VP Finance & Operations	Aug 17 '23	Sale	0.62	230	143	48,921	Aug 18 08:05 AM
Lucchino David L.	President and CEO	Aug 16 '23	Sale	0.65	2,895	1,882	642,399	Aug 18 08:01 AM
Mitrano Richard J.	VP Finance & Operations	Aug 16 '23	Sale	0.67	234	157	49,151	Aug 18 08:05 AM
Lucchino David L.	President and CEO	Aug 15 '23	Sale	0.67	2,629	1,761	645,294	Aug 16 08:59 AM
Mitrano Richard J.	VP Finance & Operations	Aug 15 '23	Sale	0.65	228	148	49,385	Aug 16 09:02 AM
Lucchino David L.	President and CEO	Aug 14 '23	Sale	0.63	2,881	1,815	647,923	Aug 16 08:59 AM
Mitrano Richard J.	VP Finance & Operations	Aug 14 '23	Sale	0.64	238	152	49,613	Aug 16 09:02 AM
Lucchino David L.	President and CEO	Aug 11 '23	Sale	0.67	2,733	1,831	650,804	Aug 14 04:07 PM
Mitrano Richard J.	VP Finance & Operations	Aug 11 '23	Sale	0.64	240	154	49,851	Aug 14 04:06 PM
Lucchino David L.	President and CEO	Aug 10 '23	Sale	0.68	2,790	1,897	653,537	Aug 14 04:07 PM
Mitrano Richard J.	VP Finance & Operations	Aug 10 '23	Sale	0.64	247	158	50,091	Aug 14 04:06 PM
Lucchino David L.	President and CEO	Aug 09 '23	Sale	0.67	2,798	1,875	656,327	Aug 10 04:04 PM
Mitrano Richard J.	VP Finance & Operations	Aug 09 '23	Sale	0.66	238	157	50,338	Aug 10 04:02 PM
Lucchino David L.	President and CEO	Aug 08 '23	Sale	0.69	2,810	1,939	659,125	Aug 10 04:04 PM
Mitrano Richard J.	VP Finance & Operations	Aug 08 '23	Sale	0.67	241	161	50,576	Aug 10 04:02 PM
Lucchino David L.	President and CEO	Aug 07 '23	Sale	0.68	2,857	1,943	661,935	Aug 09 08:51 AM
Mitrano Richard J.	VP Finance & Operations	Aug 07 '23	Sale	0.69	235	162	50,817	Aug 09 08:50 AM
Lucchino David L.	President and CEO	Aug 04 '23	Sale	0.69	2,550	1,759	664,792	Aug 09 08:51 AM
Mitrano Richard J.	VP Finance & Operations	Aug 04 '23	Sale	0.67	220	147	51,052	Aug 09 08:50 AM
Lucchino David L.	President and CEO	Aug 03 '23	Sale	0.59	2,679	1,581	667,342	Aug 04 04:10 PM
Mitrano Richard J.	VP Finance & Operations	Aug 03 '23	Sale	0.56	232	130	51,272	Aug 04 04:09 PM
Lucchino David L.	President and CEO	Aug 02 '23	Sale	0.52	2,587	1,345	670,021	Aug 04 04:10 PM
Mitrano Richard J.	VP Finance & Operations	Aug 02 '23	Sale	0.49	231	113	51,504	Aug 04 04:09 PM
Lucchino David L.	President and CEO	Aug 01 '23	Sale	0.49	2,799	1,372	672,608	Aug 02 04:36 PM
Mitrano Richard J.	VP Finance & Operations	Aug 01 '23	Sale	0.48	238	114	51,735	Aug 02 04:35 PM
Lucchino David L.	President and CEO	Jul 31 '23	Sale	0.50	2,676	1,338	675,407	Aug 02 04:36 PM
Mitrano Richard J.	VP Finance & Operations	Jul 31 '23	Sale	0.50	222	111	51,973	Aug 02 04:35 PM
Lucchino David L.	President and CEO	Jul 28 '23	Sale	0.47	2,647	1,244	678,083	Jul 31 04:05 PM
Loose Christopher R.	Chief Scientific Officer	Jul 28 '23	Sale	0.46	1,344	618	183,650	Jul 31 04:01 PM
Mitrano Richard J.	VP Finance & Operations	Jul 28 '23	Sale	0.47	223	105	52,195	Jul 31 04:09 PM
Lucchino David L.	President and CEO	Jul 27 '23	Sale	0.51	2,791	1,423	680,730	Jul 31 04:05 PM
Loose Christopher R.	Chief Scientific Officer	Jul 27 '23	Sale	0.53	1,373	728	184,994	Jul 31 04:01 PM
Mitrano Richard J.	VP Finance & Operations	Jul 27 '23	Sale	0.53	227	120	52,418	Jul 31 04:09 PM
Lucchino David L.	President and CEO	Jul 26 '23	Sale	0.52	2,609	1,357	683,521	Jul 27 04:15 PM
Loose Christopher R.	Chief Scientific Officer	Jul 26 '23	Sale	0.51	1,329	678	186,367	Jul 27 04:16 PM
Mitrano Richard J.	VP Finance & Operations	Jul 26 '23	Sale	0.53	222	118	52,645	Jul 27 04:16 PM
Lucchino David L.	President and CEO	Jul 25 '23	Sale	0.50	2,803	1,402	686,130	Jul 27 04:15 PM
Loose Christopher R.	Chief Scientific Officer	Jul 25 '23	Sale	0.50	1,390	695	187,696	Jul 27 04:16 PM
Mitrano Richard J.	VP Finance & Operations	Jul 25 '23	Sale	0.50	234	117	52,867	Jul 27 04:16 PM
Lucchino David L.	President and CEO	Jul 24 '23	Sale	0.54	2,887	1,559	688,933	Jul 25 04:56 PM
Loose Christopher R.	Chief Scientific Officer	Jul 24 '23	Sale	0.54	1,438	777	189,086	Jul 25 04:56 PM
Mitrano Richard J.	VP Finance & Operations	Jul 24 '23	Sale	0.56	234	131	53,101	Jul 25 04:55 PM
Lucchino David L.	President and CEO	Jul 21 '23	Sale	0.61	2,663	1,624	691,820	Jul 25 04:56 PM
Loose Christopher R.	Chief Scientific Officer	Jul 21 '23	Sale	0.61	1,333	813	190,524	Jul 25 04:56 PM
Mitrano Richard J.	VP Finance & Operations	Jul 21 '23	Sale	0.61	223	136	53,335	Jul 25 04:55 PM
Lucchino David L.	President and CEO	Jul 20 '23	Sale	0.64	2,710	1,734	694,483	Jul 21 04:06 PM
Loose Christopher R.	Chief Scientific Officer	Jul 20 '23	Sale	0.64	1,361	871	191,857	Jul 21 04:07 PM
Mitrano Richard J.	VP Finance & Operations	Jul 20 '23	Sale	0.64	229	147	53,558	Jul 21 04:04 PM
Lucchino David L.	President and CEO	Jul 19 '23	Sale	0.65	2,646	1,720	697,193	Jul 21 04:06 PM
Loose Christopher R.	Chief Scientific Officer	Jul 19 '23	Sale	0.65	1,335	868	193,218	Jul 21 04:07 PM
Mitrano Richard J.	VP Finance & Operations	Jul 19 '23	Sale	0.63	228	144	53,787	Jul 21 04:04 PM
Lucchino David L.	President and CEO	Jul 18 '23	Sale	0.56	2,968	1,662	699,839	Jul 19 04:14 PM
Loose Christopher R.	Chief Scientific Officer	Jul 18 '23	Sale	0.56	1,484	831	194,553	Jul 19 04:13 PM
Mitrano Richard J.	VP Finance & Operations	Jul 18 '23	Sale	0.56	249	139	54,015	Jul 19 04:16 PM
Lucchino David L.	President and CEO	Jul 17 '23	Sale	0.68	2,775	1,887	702,807	Jul 19 04:14 PM
Loose Christopher R.	Chief Scientific Officer	Jul 17 '23	Sale	0.67	1,415	948	196,037	Jul 19 04:13 PM
Mitrano Richard J.	VP Finance & Operations	Jul 17 '23	Sale	0.65	244	159	54,264	Jul 19 04:16 PM
Lucchino David L.	President and CEO	Jul 14 '23	Sale	0.59	1,815	1,071	705,582	Jul 17 04:22 PM
Loose Christopher R.	Chief Scientific Officer	Jul 14 '23	Sale	0.59	906	535	197,452	Jul 17 04:23 PM
Mitrano Richard J.	VP Finance & Operations	Jul 14 '23	Sale	0.60	148	89	54,508	Jul 17 04:20 PM
Lucchino David L.	President and CEO	Jul 13 '23	Sale	0.39	2,646	1,032	707,397	Jul 17 04:22 PM
Loose Christopher R.	Chief Scientific Officer	Jul 13 '23	Sale	0.39	1,329	518	198,358	Jul 17 04:23 PM
Mitrano Richard J.	VP Finance & Operations	Jul 13 '23	Sale	0.39	227	89	54,656	Jul 17 04:20 PM
Lucchino David L.	President and CEO	Jul 12 '23	Sale	0.39	2,649	1,033	710,043	Jul 13 04:14 PM
Loose Christopher R.	Chief Scientific Officer	Jul 12 '23	Sale	0.39	1,335	521	199,687	Jul 13 04:42 PM
Mitrano Richard J.	VP Finance & Operations	Jul 12 '23	Sale	0.40	220	88	54,883	Jul 13 04:09 PM
Lucchino David L.	President and CEO	Jul 11 '23	Sale	0.37	2,731	1,010	712,692	Jul 13 04:14 PM
Loose Christopher R.	Chief Scientific Officer	Jul 11 '23	Sale	0.37	1,363	504	201,022	Jul 13 04:42 PM
Mitrano Richard J.	VP Finance & Operations	Jul 11 '23	Sale	0.37	228	84	55,103	Jul 13 04:09 PM
Lucchino David L.	President and CEO	Jul 10 '23	Sale	0.38	2,591	985	442,696	Jul 11 05:24 PM
Loose Christopher R.	Chief Scientific Officer	Jul 10 '23	Sale	0.37	1,304	482	66,023	Jul 11 05:35 PM
Mitrano Richard J.	VP Finance & Operations	Jul 10 '23	Sale	0.37	220	81	32,605	Jul 11 05:29 PM
Lucchino David L.	President and CEO	Jul 07 '23	Sale	0.35	2,634	922	436,196	Jul 11 05:24 PM
Loose Christopher R.	Chief Scientific Officer	Jul 07 '23	Sale	0.36	1,306	470	62,781	Jul 11 05:35 PM
Mitrano Richard J.	VP Finance & Operations	Jul 07 '23	Sale	0.36	220	79	32,067	Jul 11 05:29 PM
Lucchino David L.	President and CEO	Jul 06 '23	Sale	0.34	2,773	943	429,739	Jul 07 04:56 PM
Loose Christopher R.	Chief Scientific Officer	Jul 06 '23	Sale	0.34	1,384	471	57,758	Jul 07 04:54 PM
Mitrano Richard J.	VP Finance & Operations	Jul 06 '23	Sale	0.35	224	78	31,529	Jul 07 05:06 PM

Open in Screener

DYN

Dyne Therapeutics Inc

May 20 • 04:00PM ET

35.38

Dollar change +7.70
Percentage change 27.82	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

DYN Dyne Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWN IBB SCHA LABU VTWO IWO DWAS

Index	RUT	P/E	-	EPS (ttm)	-3.97	Insider Own	34.17%	Shs Outstand	61.47M	Perf Week	32.91%
Market Cap	2.87B	Forward P/E	-	EPS next Y	-3.28	Insider Trans	-10.71%	Shs Float	53.39M	Perf Month	48.28%
Income	-257.40M	PEG	-	EPS next Q	-0.75	Inst Own	82.59%	Short Float	18.04%	Perf Quarter	55.58%
Sales	0.00M	P/S	-	EPS this Y	21.41%	Inst Trans	-3.15%	Short Ratio	7.44	Perf Half Y	262.31%
Book/sh	5.49	P/B	6.45	EPS next Y	-5.74%	ROA	-63.48%	Short Interest	9.63M	Perf Year	168.84%
Cash/sh	5.59	P/C	6.33	EPS next 5Y	-	ROE	-71.50%	52W Range	6.40 - 30.27	Perf YTD	166.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-106.26%	ROI	-51.49%	52W High	16.89%	Beta	1.12
Dividend TTM	-	Quick Ratio	21.83	Sales past 5Y	0.00%	Gross Margin	-	52W Low	452.81%	ATR (14)	2.05
Dividend Ex-Date	-	Current Ratio	21.83	EPS Y/Y TTM	-18.88%	Oper. Margin	0.00%	RSI (14)	77.09	Volatility	8.32% 6.23%
Employees	141	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	45.67
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-3.25%	Payout	-	Rel Volume	3.70	Prev Close	27.68
Sales Surprise	-100.00%	EPS Surprise	-1.25%	Sales Q/Q	-	Earnings	May 02 AMC	Avg Volume	1.29M	Price	35.38
SMA20	35.42%	SMA50	33.44%	SMA200	111.64%	Trades		Volume	4,597,923	Change	27.82%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15
Oct-12-20	Initiated	Stifel	Buy	$29
Oct-12-20	Initiated	Piper Sandler	Overweight	$34
Oct-12-20	Initiated	JP Morgan	Overweight	$27
Oct-12-20	Initiated	Jefferies	Buy	$47

Show Previous Ratings

May-20-24 05:53PM	Why Is Dyne Therapeutics Stock Soaring On Monday? (Benzinga) +27.82%
04:27PM	Dyne Therapeutics Launches $300 Million Share Offering (MT Newswires)
04:07PM	Why Dyne Therapeutics, With A 166% Run This Year, Just Catapulted Again (Investor's Business Daily)
04:01PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
11:22AM	Update: Dyne Shares Rise After Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles (MT Newswires)
09:40AM	Loading…
09:40AM	HC Wainwright Adjusts Price Target on Dyne Therapeutics to $48 From $46, Maintains Buy Rating (MT Newswires)
09:12AM	Sector Update: Health Care Stocks Mixed Pre-Bell Monday (MT Newswires)
08:02AM	Dyne shares jump on trial data for muscle disease drugs (BioPharma Dive)
07:47AM	Dyne Says Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles (MT Newswires)
07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:30AM	Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints (GlobeNewswire)
May-19-24 08:00AM	Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET (GlobeNewswire)
May-04-24 05:31AM	Dyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst Projections (GuruFocus.com)
May-02-24 11:52PM	DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:10PM	Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
07:32AM	Loading…
Apr-30-24 07:32AM	Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target (MT Newswires)
Mar-27-24 04:05PM	Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer (GlobeNewswire) +6.42%
08:30AM	Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium (GlobeNewswire)
Mar-25-24 12:28PM	United Airlines, Dyne Therapeutics fall; Lucid Group, Century Aluminum rise, Monday, 3/25/2024 (Associated Press Finance) -7.72%
07:30AM	Dyne Therapeutics Announces CEO Transition (GlobeNewswire)
Mar-13-24 07:30AM	Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days (GlobeNewswire)
Mar-07-24 01:19PM	Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ... (GuruFocus.com)
Mar-05-24 10:53AM	DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.64%
07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-02-24 12:00AM	CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) +7.69%
Feb-14-24 04:15PM	Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Feb-01-24 07:30AM	Dyne Therapeutics to Present at February Investor Conferences (GlobeNewswire)
Jan-26-24 11:01PM	Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com) +18.21%
Jan-22-24 10:14PM	7 Speculative Stocks to Double Your Money THIS Year (InvestorPlace)
01:12PM	Loading…
Jan-12-24 01:12PM	Hedge Fund and Insider Trading News: Steve Cohen, Crispin Odey, Bill Ackman, Saba Capital Management, Moab Capital Partners, Eisler Capital, Dyne Therapeutics Inc. (DYN), and More (Insider Monkey)
Jan-11-24 04:05PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -5.36%
Jan-05-24 09:02AM	CEO & President Joshua Brumm Sells 269,719 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com) -7.37%
07:30AM	Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-24 10:46PM	Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock (GlobeNewswire) +31.28%
04:37PM	Todays Stock Market Movers: Walgreens, Mobileye, Apple, APA, Callon, Peloton, Sunrun, and More (Barrons.com)
12:39PM	These Stocks Are Moving the Most Today: Walgreens, Mobileye, Apple, APA, Callon, Peloton, Sunrun, and More (Barrons.com)
Jan-03-24 04:25PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +13.09%
02:46PM	Biotech Stocks Dyne, Agios Leap on Muscle-Disorder Drugs' Trial Results (The Wall Street Journal)
02:01PM	Biotechs Dyne, Agios Leap on Muscle-Disorder Drugs Trial Results (The Wall Street Journal)
08:19AM	Why Is Dyne Therapeutics (DYN) Stock Up 39% Today? (InvestorPlace)
06:30AM	Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE Platform in Developing Therapeutics for Rare Muscle Diseases (GlobeNewswire)
Jan-02-24 04:05PM	Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials (GlobeNewswire)
Nov-13-23 06:59PM	3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition (InvestorPlace)
Nov-07-23 07:30AM	Dyne Therapeutics to Present at November Investor Conferences (GlobeNewswire) +14.58%
Oct-31-23 05:36AM	Dyne Therapeutics Inc (DYN) Reports Q3 2023 Financial Results and Progress in Clinical Trials (GuruFocus.com)
01:11AM	The Dyne Therapeutics Inc (DYN) Company: A Short SWOT Analysis (GuruFocus.com)
Oct-30-23 07:30AM	Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones (GlobeNewswire) +10.57%
Sep-28-23 07:30AM	Dyne Therapeutics to Present at October Investor Conferences (GlobeNewswire)
Sep-20-23 04:05PM	Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire) -5.48%
Sep-15-23 01:52PM	Why Shares of Dyne Therapeutics Fell This Week (Motley Fool)
Sep-14-23 01:22PM	Insider Sell: Chief Medical Officer Wildon Farwell Sells 1,707 Shares of Dyne Therapeutics Inc (GuruFocus.com)
Sep-05-23 07:30AM	Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-03-23 07:30AM	Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jun-16-23 08:46AM	SMID Caps Are Poised for a Good Run, Says Oppenheimer And These 2 Stocks Fit the Bill With Over 100% Upside (TipRanks) -9.50%
Jun-01-23 07:30AM	Dyne Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-25-23 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101 (GlobeNewswire) -7.56%
May-17-23 11:25AM	We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate (Simply Wall St.)
07:30AM	Dyne Therapeutics Preclinical Data Demonstrating FORCE Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting (GlobeNewswire)
May-11-23 07:30AM	Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
May-03-23 07:35AM	Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference (GlobeNewswire)
May-02-23 04:46PM	Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE Platform Delivery to CNS (GlobeNewswire)
Mar-23-23 07:30AM	Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-20-23 07:30AM	Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Mar-07-23 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-02-23 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire) +5.06%
Mar-01-23 09:00AM	How to chart anchored VWAP multiple time frames: Brian Shannon, CMT (Yahoo Finance Video) +5.82%
Feb-27-23 04:40PM	Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock (Benzinga) +12.76%
Feb-05-23 05:03AM	TipRanks Perfect 10 List: Strong Catalysts Confirm the Bull Thesis on These 2 Stocks (TipRanks)
Jan-19-23 08:23AM	Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics (Zacks)
Jan-18-23 08:49AM	5 Stocks to Buy as the Drug Industry Bets Big on Innovation (Zacks)
Jan-10-23 12:00PM	All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong Buy (Zacks)
Jan-03-23 07:30AM	Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-22 09:55AM	Does Dyne Therapeutics, Inc. (DYN) Have the Potential to Rally 84% as Wall Street Analysts Expect? (Zacks)
Dec-09-22 09:55AM	Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock Now (Zacks) -5.05%
Dec-08-22 08:10AM	Will Dyne Therapeutics (NASDAQ:DYN) Spend Its Cash Wisely? (Simply Wall St.)
Nov-30-22 09:55AM	Wall Street Analysts Predict a 141% Upside in Dyne Therapeutics, Inc. (DYN): Here's What You Should Know (Zacks) +8.43%
Nov-03-22 07:30AM	Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) +9.63%
Nov-02-22 07:30AM	Dyne Therapeutics to Present at Investor Conferences in November (GlobeNewswire)
Oct-31-22 07:30AM	Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Oct-12-22 06:45AM	Dyne founder heads up new RNA-editing startup (American City Business Journals)
Oct-11-22 04:10PM	Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress (GlobeNewswire)
Sep-27-22 07:30AM	Dyne Therapeutics to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire) -9.57%
Sep-12-22 07:00AM	Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During Spotlight on the Clinic Virtual Event (GlobeNewswire)
Sep-06-22 04:30PM	Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire) +5.32%
07:01AM	Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
07:00AM	Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-29-22 07:30AM	Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development (GlobeNewswire)
Aug-10-22 07:30AM	Dyne Therapeutics Announces Breakthrough Article Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research (GlobeNewswire) +7.75%
Aug-04-22 07:30AM	Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Jul-18-22 10:00AM	Best Momentum Stocks to Buy for July 18th (Zacks) -5.56%
Jul-12-22 02:54PM	Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew (Benzinga) +5.94%
07:30AM	Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jul-05-22 07:30AM	Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire) +17.22%
Jul-01-22 06:58AM	Will Dyne Therapeutics (NASDAQ:DYN) Spend Its Cash Wisely? (Simply Wall St.)
Jun-03-22 07:30AM	Dyne Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire) +5.05%
May-16-22 07:30AM	Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown (GlobeNewswire)
May-02-22 04:05PM	Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) +6.77%
Mar-17-22 08:45AM	selfologi Chooses Digital Technology Consulting Partner Grid Dynamics to Launch Its Cosmetic Treatment Platform (ACCESSWIRE)

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McNeill Jonathan	Chief Business Officer	May 16 '24	Sale	28.27	2,774	78,420	136,634	May 17 09:03 PM
HIGH SUSANNA GATTI	Chief Operating Officer	May 16 '24	Sale	28.27	2,738	77,402	154,062	May 17 09:05 PM
Beskrovnaya Oxana	Chief Scientific Officer	May 16 '24	Sale	28.27	2,705	76,469	149,647	May 17 09:07 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	May 16 '24	Sale	28.27	2,588	73,162	116,695	May 17 09:04 PM
Farwell Wildon	Chief Medical Officer	May 16 '24	Sale	28.27	2,381	67,310	148,179	May 17 09:06 PM
Farwell Wildon	Chief Medical Officer	Mar 12 '24	Sale	25.58	1,030	26,347	150,560	Mar 12 09:58 PM
Brumm Joshua T	CEO & President	Mar 11 '24	Option Exercise	5.54	50,000	277,000	604,385	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 11 '24	Option Exercise	5.54	17,825	98,750	159,009	Mar 13 06:04 AM
Brumm Joshua T	CEO & President	Mar 11 '24	Sale	25.67	66,387	1,704,142	537,998	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 11 '24	Sale	25.50	19,601	499,842	139,408	Mar 13 06:04 AM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 11 '24	Sale	25.28	2,672	67,542	119,283	Mar 12 09:57 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 11 '24	Sale	25.70	2,292	58,904	156,800	Mar 13 06:04 AM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 11 '24	Sale	25.70	2,081	53,482	152,352	Mar 12 09:42 PM
Farwell Wildon	Chief Medical Officer	Mar 11 '24	Sale	25.70	1,585	40,734	151,590	Mar 12 09:58 PM
Brumm Joshua T	CEO & President	Mar 08 '24	Option Exercise	5.54	363,343	2,012,920	917,728	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 08 '24	Option Exercise	5.54	90,000	498,600	231,184	Mar 13 06:04 AM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 08 '24	Option Exercise	5.54	86,252	477,836	208,207	Mar 12 09:57 PM
Brumm Joshua T	CEO & President	Mar 08 '24	Sale	25.93	363,343	9,421,634	554,385	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 08 '24	Sale	26.24	90,000	2,361,531	141,184	Mar 13 06:04 AM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 08 '24	Sale	26.22	86,252	2,261,465	121,955	Mar 12 09:57 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 08 '24	Sale	26.67	27,199	725,344	159,092	Mar 13 06:04 AM
Farwell Wildon	Chief Medical Officer	Mar 07 '24	Sale	25.86	9,921	256,585	153,175	Mar 11 09:52 PM
Brumm Joshua T	CEO & President	Mar 07 '24	Sale	25.85	9,086	234,873	554,385	Mar 11 09:57 PM
McNeill Jonathan	Chief Business Officer	Mar 07 '24	Sale	25.85	2,434	62,919	141,184	Mar 11 09:50 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 07 '24	Sale	25.85	2,373	61,342	154,433	Mar 11 09:56 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 07 '24	Sale	25.85	2,273	58,757	121,955	Mar 11 09:45 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 07 '24	Sale	25.85	1,591	41,127	186,291	Mar 11 09:56 PM
Brumm Joshua T	CEO & President	Mar 01 '24	Option Exercise	5.54	94,480	523,419	657,951	Mar 01 09:38 PM
McNeill Jonathan	Chief Business Officer	Mar 01 '24	Option Exercise	0.73	24,260	17,710	167,878	Mar 01 09:37 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 01 '24	Option Exercise	1.03	9,311	9,590	133,539	Mar 01 09:37 PM
Brumm Joshua T	CEO & President	Mar 01 '24	Sale	29.04	94,480	2,743,718	563,471	Mar 01 09:38 PM
Rhodes Jason P	Director	Mar 01 '24	Sale	30.05	46,534	1,398,347	847,388	Mar 05 05:08 PM
Atlas Venture Opportunity Fund	10% Owner	Mar 01 '24	Sale	30.05	29,435	884,522	1,458,691	Mar 05 05:07 PM
McNeill Jonathan	Chief Business Officer	Mar 01 '24	Sale	28.63	24,260	694,495	143,618	Mar 01 09:37 PM
Atlas Venture Opportunity Fund	10% Owner	Mar 01 '24	Sale	30.05	17,099	513,825	847,388	Mar 05 05:07 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 01 '24	Sale	28.25	9,311	262,999	124,228	Mar 01 09:37 PM
Brumm Joshua T	CEO & President	Feb 29 '24	Option Exercise	5.54	5,520	30,581	568,991	Mar 01 09:38 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Feb 29 '24	Option Exercise	1.03	3,429	3,532	127,657	Mar 01 09:37 PM
McNeill Jonathan	Chief Business Officer	Feb 29 '24	Option Exercise	0.73	4,268	3,116	147,886	Mar 01 09:37 PM
Brumm Joshua T	CEO & President	Feb 29 '24	Sale	27.50	5,520	151,800	563,471	Mar 01 09:38 PM
McNeill Jonathan	Chief Business Officer	Feb 29 '24	Sale	27.50	4,268	117,370	143,618	Mar 01 09:37 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Feb 29 '24	Sale	27.50	3,429	94,298	124,228	Mar 01 09:37 PM
Rhodes Jason P	Director	Feb 28 '24	Sale	24.84	190,920	4,741,804	864,487	Feb 28 07:15 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 28 '24	Sale	24.84	154,674	3,841,576	5,698,091	Feb 28 07:13 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 28 '24	Sale	24.84	36,246	900,228	864,487	Feb 28 07:13 PM
Rhodes Jason P	Director	Feb 27 '24	Sale	24.41	368,699	8,998,426	877,806	Feb 28 07:15 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 27 '24	Sale	24.41	298,702	7,290,088	5,852,765	Feb 28 07:13 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 27 '24	Sale	24.41	69,997	1,708,338	877,806	Feb 28 07:13 PM
Rhodes Jason P	Director	Feb 26 '24	Sale	23.72	248,219	5,886,673	903,527	Feb 28 07:15 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 26 '24	Sale	23.72	201,095	4,769,096	6,151,467	Feb 28 07:13 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 26 '24	Sale	23.72	47,124	1,117,577	903,527	Feb 28 07:13 PM
Rhodes Jason P	Director	Feb 23 '24	Sale	22.70	196,928	4,470,266	920,843	Feb 23 06:59 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 23 '24	Sale	22.70	159,542	3,621,603	6,352,562	Feb 23 06:58 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 23 '24	Sale	22.70	37,386	848,662	920,843	Feb 23 06:58 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 22 '24	Sale	22.66	119,360	2,704,698	6,512,104	Feb 23 06:58 PM
Rhodes Jason P	Director	Feb 22 '24	Sale	22.66	119,360	2,704,698	6,512,104	Feb 23 06:59 PM
Rhodes Jason P	Director	Feb 21 '24	Sale	22.57	184,501	4,164,817	6,631,464	Feb 23 06:59 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 21 '24	Sale	22.57	184,501	4,164,817	6,631,464	Feb 23 06:58 PM
Rhodes Jason P	Director	Feb 20 '24	Sale	22.72	169,539	3,852,653	6,815,965	Feb 20 06:36 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 20 '24	Sale	22.72	169,539	3,852,653	6,815,965	Feb 20 06:35 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 16 '24	Sale	23.14	162,707	3,765,040	6,985,504	Feb 20 06:35 PM
Rhodes Jason P	Director	Feb 16 '24	Sale	23.14	162,707	3,765,040	6,985,504	Feb 20 06:36 PM
Rhodes Jason P	Director	Feb 15 '24	Sale	23.89	177,906	4,249,600	7,148,211	Feb 20 06:36 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 15 '24	Sale	23.89	177,906	4,249,600	7,148,211	Feb 20 06:35 PM
Farwell Wildon	Chief Medical Officer	Feb 12 '24	Sale	25.07	5,493	137,710	163,503	Feb 14 04:27 PM
McNeill Jonathan	Chief Business Officer	Jan 26 '24	Option Exercise	0.73	20,000	14,600	163,618	Jan 26 07:48 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 26 '24	Option Exercise	1.03	13,000	13,390	137,228	Jan 26 07:47 PM
McNeill Jonathan	Chief Business Officer	Jan 26 '24	Sale	24.53	20,000	490,510	143,618	Jan 26 07:48 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 26 '24	Sale	24.34	13,000	316,420	124,228	Jan 26 07:47 PM
Farwell Wildon	Chief Medical Officer	Jan 26 '24	Sale	25.00	100	2,500	168,996	Jan 26 07:49 PM
Kersten Dirk	Director	Jan 09 '24	Buy	17.50	1,714,285	29,999,988	6,416,793	Jan 11 04:31 PM
Brumm Joshua T	CEO & President	Jan 04 '24	Option Exercise	5.16	218,536	1,127,092	803,507	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 04 '24	Option Exercise	1.03	22,674	23,354	199,259	Jan 04 09:48 PM
McNeill Jonathan	Chief Business Officer	Jan 04 '24	Option Exercise	0.73	2,009	1,467	145,627	Jan 04 09:47 PM
Brumm Joshua T	CEO & President	Jan 04 '24	Sale	18.51	218,536	4,045,958	584,971	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 04 '24	Sale	18.13	42,453	769,673	156,806	Jan 04 09:48 PM
McNeill Jonathan	Chief Business Officer	Jan 04 '24	Sale	18.04	2,009	36,242	143,618	Jan 04 09:47 PM
Brumm Joshua T	CEO & President	Jan 03 '24	Option Exercise	1.03	51,183	52,718	636,154	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 03 '24	Option Exercise	1.03	45,326	46,686	221,911	Jan 04 09:48 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 03 '24	Option Exercise	1.03	13,000	13,390	137,228	Jan 04 09:46 PM
McNeill Jonathan	Chief Business Officer	Jan 03 '24	Option Exercise	0.73	17,991	13,133	161,609	Jan 04 09:47 PM
Brumm Joshua T	CEO & President	Jan 03 '24	Sale	19.28	51,183	986,957	584,971	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 03 '24	Sale	18.98	45,326	860,313	176,585	Jan 04 09:48 PM
McNeill Jonathan	Chief Business Officer	Jan 03 '24	Sale	18.74	17,991	337,062	143,618	Jan 04 09:47 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 03 '24	Sale	18.81	13,000	244,530	124,228	Jan 04 09:46 PM
McNeill Jonathan	Chief Business Officer	Jan 02 '24	Sale	13.10	11,900	155,890	143,618	Jan 04 09:47 PM
Scalzo Richard William	See Remarks	Dec 14 '23	Sale	12.02	2,376	28,560	124,228	Dec 14 04:59 PM
Farwell Wildon	Chief Medical Officer	Dec 12 '23	Sale	10.55	978	10,318	169,096	Dec 12 05:33 PM
Brumm Joshua T	See Remarks	Dec 11 '23	Sale	10.72	7,585	81,311	584,971	Dec 12 05:33 PM
Farwell Wildon	Chief Medical Officer	Dec 11 '23	Sale	10.72	1,688	18,095	170,074	Dec 12 05:33 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Dec 11 '23	Sale	10.72	1,616	17,324	187,882	Dec 12 05:34 PM
Beskrovnaya Oxana	Chief Scientific Officer	Dec 11 '23	Sale	10.72	1,467	15,726	176,585	Dec 12 05:32 PM
Scalzo Richard William	See Remarks	Dec 11 '23	Sale	10.72	1,380	14,794	126,604	Dec 12 05:35 PM
McNeill Jonathan	Chief Business Officer	Dec 11 '23	Sale	10.72	1,245	13,346	155,518	Dec 12 05:34 PM
Scalzo Richard William	See Remarks	Dec 06 '23	Sale	12.01	1,872	22,483	127,984	Dec 06 06:13 PM
Scalzo Richard William	See Remarks	Dec 04 '23	Sale	12.01	681	8,179	129,856	Dec 06 06:13 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Nov 02 '23	Sale	7.40	9,939	73,549	94,605	Nov 02 05:16 PM
Brumm Joshua T	See Remarks	Sep 18 '23	Sale	9.41	12,032	113,221	233,679	Sep 20 04:47 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Sep 18 '23	Sale	9.41	2,672	25,144	104,544	Sep 20 04:48 PM
Beskrovnaya Oxana	Chief Scientific Officer	Sep 18 '23	Sale	9.41	1,436	13,513	84,334	Sep 20 04:47 PM

Open in Screener

DAWN

Day One Biopharmaceuticals Inc

May 20 • 04:00PM ET

15.97

Dollar change -0.20
Percentage change -1.24	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

DAWN Day One Biopharmaceuticals Inc daily Stock Chart

Held by: VTI IWM VXF VB VBR IWO IBB SCHA VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-2.49	Insider Own	30.65%	Shs Outstand	87.23M	Perf Week	-0.50%
Market Cap	1.40B	Forward P/E	-	EPS next Y	-2.14	Insider Trans	-0.93%	Shs Float	60.61M	Perf Month	6.75%
Income	-208.94M	PEG	-	EPS next Q	-0.75	Inst Own	73.18%	Short Float	18.46%	Perf Quarter	7.25%
Sales	0.00M	P/S	-	EPS this Y	-19.05%	Inst Trans	2.05%	Short Ratio	10.31	Perf Half Y	36.26%
Book/sh	3.40	P/B	4.70	EPS next Y	24.21%	ROA	-64.27%	Short Interest	11.19M	Perf Year	22.09%
Cash/sh	3.64	P/C	4.39	EPS next 5Y	-	ROE	-69.97%	52W Range	9.67 - 18.07	Perf YTD	9.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-84.59%	ROI	-70.39%	52W High	-11.62%	Beta	-1.46
Dividend TTM	-	Quick Ratio	10.93	Sales past 5Y	0.00%	Gross Margin	-	52W Low	65.15%	ATR (14)	0.92
Dividend Ex-Date	-	Current Ratio	10.93	EPS Y/Y TTM	-9.93%	Oper. Margin	0.00%	RSI (14)	49.76	Volatility	3.81% 7.01%
Employees	155	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.55	Target Price	35.78
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-22.24%	Payout	-	Rel Volume	0.43	Prev Close	16.17
Sales Surprise	-	EPS Surprise	-8.58%	Sales Q/Q	-	Earnings	May 06 AMC	Avg Volume	1.09M	Price	15.97
SMA20	-1.76%	SMA50	3.59%	SMA200	14.93%	Trades		Volume	469,882	Change	-1.24%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-24-24	Reiterated	Needham	Buy	$30 → $33
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform	$34 → $9
Feb-08-23	Initiated	CapitalOne	Overweight	$40
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy	$35
Dec-14-22	Initiated	Needham	Buy	$40
Dec-05-22	Initiated	Goldman	Buy	$45
Dec-01-22	Initiated	BofA Securities	Buy	$34

May-07-24 09:25AM	HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $40 From $50, Maintains Buy Rating (MT Newswires)
May-06-24 10:53PM	DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024 (InvestorPlace)
04:30PM	Day One Reports First Quarter 2024 Financial Results and Corporate Progress (GlobeNewswire)
03:22AM	Day One Biopharmaceuticals Insider Sold Shares Worth $1,081,191, According to a Recent SEC Filing (MT Newswires)
May-04-24 02:31AM	Insider Sale at Day One Biopharmaceuticals Inc (DAWN) (GuruFocus.com)
03:56PM	Loading…
Apr-23-24 03:56PM	Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor (GlobeNewswire) +8.19%
03:54PM	Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment (MT Newswires)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Feb-28-24 04:32AM	Day One Biopharmaceuticals Inc (DAWN) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
Feb-26-24 04:30PM	Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress (GlobeNewswire)
Jan-31-24 05:12PM	Dwayne 'The Rock' Johnson's net worth: How the new TKO Board Member built his wealth from $7 (TheStreet)
Jan-17-24 08:00AM	Day One Announces Two New Appointments to Board of Directors (GlobeNewswire)
Dec-19-23 08:00AM	Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-27-23 10:00AM	Milei to Send Shock Package to Argentinas Congress on Day One (Bloomberg)
Nov-17-23 07:00AM	Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine (GlobeNewswire)
08:00AM	Loading…
Nov-14-23 08:00AM	Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire) +6.85%
Nov-06-23 05:16PM	Day One Biopharmaceuticals Inc (DAWN) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
04:30PM	Day One Reports Third Quarter 2023 Financial Results and Corporate Progress (GlobeNewswire)
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Oct-30-23 07:27PM	Apples Journal app has arrived heres whats good and bad (TechCrunch) +17.01%
08:00AM	Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)
Oct-23-23 01:20PM	Hedge Fund and Insider Trading News: Bill Ackman, Nelson Peltz, Dan Loeb, Coltrane Asset Management, Day One Biopharmaceuticals, Inc. (DAWN), Central Securities Corp. (CET), and More (Insider Monkey)
Oct-20-23 10:20AM	Tesla Stock Had a Horrible Day. Heres What Comes Next. (Barrons.com)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-11-23 09:02PM	Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)
Aug-16-23 08:00AM	Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience (GlobeNewswire)
Aug-10-23 02:28PM	FMR LLC Reduces Stake in Day One Biopharmaceuticals Inc (GuruFocus.com)
Aug-07-23 04:30PM	Day One Reports Second Quarter 2023 Financial Results and Corporate Progress (GlobeNewswire)
Jun-17-23 08:29AM	Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is favoured by institutional owners who hold 54% of the company (Simply Wall St.)
Jun-12-23 08:00AM	Day One Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
12:38PM	Loading…
Jun-08-23 12:38PM	Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More (Zacks) -8.19%
07:00AM	KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA (PR Newswire)
Jun-06-23 10:31PM	Day One Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	Day One Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-05-23 04:06PM	ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Dips (Investor's Business Daily)
12:30PM	Why Shares of Day One Pharmaceuticals Are Up Monday (Motley Fool)
Jun-04-23 12:45PM	Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (GlobeNewswire)
May-30-23 08:00AM	Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference (GlobeNewswire)
May-25-23 08:30PM	CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
05:00PM	Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-01-23 09:00AM	Day One Reports First Quarter 2023 Financial Results and Corporate Progress (GlobeNewswire) +16.69%
Apr-30-23 09:57AM	We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth (Simply Wall St.)
Apr-26-23 09:31AM	Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +8.18%
Apr-21-23 01:02PM	Leaked: Apple's Secret Health Play Could Push Out Smaller Apps (TheStreet.com) +5.38%
11:44AM	A Daily Journal For iPhone: Apple Weighs Day One-Like Health App For iPhone Users (Benzinga)
Apr-12-23 08:00AM	Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress (GlobeNewswire)
Mar-21-23 05:30AM	Credit Suisse sets up Hong Kong-style hawker stalls to treat investors to dim sum, pineapple buns at what could be its swan song conference (South China Morning Post)
Mar-06-23 04:30PM	Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress (GlobeNewswire)
Feb-27-23 08:00AM	Day One to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-15-23 10:24AM	Billionaire Steve Cohen Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks)
Jan-09-23 08:57AM	Day One Biopharmaceuticals Shares Jump As Pediatric Brain Cancer Candidate Shows Encouraging Responses (Benzinga)
08:30AM	Day One to submit its glioma drug to the FDA this year (MarketWatch)
Jan-08-23 05:00PM	Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma (GlobeNewswire)
Jan-03-23 01:04AM	Startups spring from ashes of Big Tech purge (Reuters) -5.90%
01:00AM	REFILE-FOCUS-Startups spring from ashes of Big Tech purge (Reuters)
Dec-20-22 08:00AM	Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-14-22 01:02PM	This Pediatric Cancer Company Makes It To Analyst's Conviction List (Benzinga) +7.51%
Dec-05-22 09:05AM	Is This the DAWN of a Rally for Day One Biopharmaceuticals? (TheStreet.com)
Nov-21-22 08:33AM	We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate (Simply Wall St.)
Nov-17-22 07:00AM	Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-11-22 07:00AM	Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting (GlobeNewswire)
Nov-07-22 04:30PM	Day One Reports Third Quarter 2022 Financial Results and Corporate Progress (GlobeNewswire)
Oct-17-22 08:00AM	Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101) (GlobeNewswire) -5.80%
Sep-12-22 08:30AM	Day One Appoints Garry Nicholson as Chairman of the Board of Directors (GlobeNewswire)
Aug-09-22 08:50AM	Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price Strength (Zacks) -6.72%
Aug-04-22 04:30PM	Day One Reports Second Quarter 2022 Financial Results and Corporate Progress (GlobeNewswire) +6.90%
Aug-02-22 08:00AM	Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire) +6.63%
Jul-29-22 11:33AM	What Percentage Of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Do Insiders Own? (Simply Wall St.)
Jul-18-22 09:55AM	Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a Bet (Zacks) -5.28%
Jun-30-22 01:08PM	Biotech ETF Tops in June: 5 Stocks That Outperform (Zacks)
Jun-23-22 07:26PM	Insiders Are Flashing a Strong Buy Signal for These 2 Stocks (TipRanks) +8.99%
Jun-21-22 08:30AM	Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jun-15-22 02:45PM	Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade (Investor's Business Daily)
05:41AM	Here's How Day One Biopharmaceuticals Stock Could Keep Climbing (Motley Fool)
Jun-14-22 08:00PM	Day One Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +5.82%
05:42PM	Day One Stock Is up 139% This Week. How Much Higher Can It Go? (TipRanks)
05:34PM	Peninsula biotech looks to raise $144M after childhood brain cancer data, big stock jump (American City Business Journals)
09:05AM	We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate (Simply Wall St.)
07:30AM	Day One Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-13-22 04:17PM	Day One Biopharmaceuticals Scores Triple-Digit Gain With Bullish Numbers In Brain Cancer (Investor's Business Daily) +125.98%
07:56AM	Why Day One Biopharma Shares Are Surging Today (Benzinga)
Jun-12-22 05:00PM	Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma (GlobeNewswire)
May-23-22 08:30AM	Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors (GlobeNewswire)
May-12-22 04:30PM	Day One Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-10-22 04:26PM	EXCLUSIVE: Play Ball! USA Pickleball And Day One Beverages Team Up, Launch Co-Branded CBD Recovery Cream (Benzinga)
Apr-06-22 08:30AM	Day One to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-07-22 07:30AM	Day One Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Progress (GlobeNewswire)
Feb-28-22 04:05PM	Day One to Participate in the Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Jan-24-22 04:51AM	Is Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Trading At A 41% Discount? (Simply Wall St.)
Jan-05-22 08:00AM	Day One to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-21 10:49AM	Judge Orders Live Nation To Stop Promoting Coachella Day One 22 Festival (TheStreet.com)
Nov-25-21 04:55AM	We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth (Simply Wall St.)
Nov-22-21 07:00AM	Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors (GlobeNewswire) -5.37%
Nov-18-21 08:00AM	Day One to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-08-21 04:50PM	Day One Reports Third Quarter 2021 Financial Results and Corporate Progress (GlobeNewswire) -5.70%
Nov-03-21 08:00AM	Day One Announces Presentation at 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting (GlobeNewswire)
Oct-20-21 09:35AM	Crypto Hits the Mainstream as Bitcoin ETF Beats Expectations (FX Empire)
Sep-13-21 07:00AM	Day One Appoints Jaa Roberson as Chief People Officer (GlobeNewswire) -8.93%
Aug-27-21 07:08AM	Insiders who bought into Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) earlier this year might wish they'd invested more as stock gained 12% (Simply Wall St.)
Aug-17-21 07:00AM	Day One Appoints Scott Garland to Board of Directors (GlobeNewswire)

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 16 '24	Sale	16.08	7,873	126,588	654,728	May 17 06:27 PM
Dubow Adam	GENERAL COUNSEL	May 16 '24	Sale	16.08	3,253	52,304	21,731	May 17 06:11 PM
York Charles N II	COO, CFO AND SECRETARY	May 16 '24	Sale	16.08	2,675	43,011	224,868	May 17 06:15 PM
Blackman Samuel C.	HEAD OF R&D	May 16 '24	Sale	16.08	2,267	36,450	1,171,081	May 17 06:18 PM
Blackman Samuel C.	HEAD OF R&D	May 10 '24	Sale	16.37	10,000	163,743	1,164,662	May 14 06:13 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 03 '24	Sale	17.85	9,154	163,417	642,602	May 03 06:48 PM
York Charles N II	COO, CFO AND SECRETARY	May 03 '24	Sale	17.85	8,078	144,214	217,293	May 03 06:44 PM
York Charles N II	COO, CFO AND SECRETARY	May 02 '24	Sale	17.90	200	3,579	225,371	May 03 06:44 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 02 '24	Sale	17.94	6	108	651,756	May 03 06:48 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 01 '24	Sale	17.88	70,051	1,252,183	651,762	May 03 06:48 PM
York Charles N II	COO, CFO AND SECRETARY	May 01 '24	Sale	17.89	52,183	933,397	225,571	May 03 06:44 PM
Blackman Samuel C.	HEAD OF R&D	Apr 18 '24	Sale	16.02	10,000	160,163	1,174,662	Apr 22 06:36 PM
Blackman Samuel C.	HEAD OF R&D	Mar 25 '24	Sale	16.01	10,000	160,055	1,184,662	Mar 26 06:09 PM
Blackman Samuel C.	HEAD OF R&D	Mar 11 '24	Sale	15.24	30,000	457,314	1,194,662	Mar 13 04:24 PM
Blackman Samuel C.	HEAD OF R&D	Feb 27 '24	Sale	16.11	20,000	322,166	1,224,662	Feb 28 07:55 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Feb 16 '24	Sale	15.25	7,615	116,114	721,813	Feb 20 06:14 PM
Dubow Adam	GENERAL COUNSEL	Feb 16 '24	Sale	15.25	3,242	49,434	16,585	Feb 20 06:48 PM
York Charles N II	COO, CFO AND SECRETARY	Feb 16 '24	Sale	15.25	2,666	40,651	277,754	Feb 20 06:36 PM
Blackman Samuel C.	HEAD OF RESEARCH AND DEVELOPME	Feb 16 '24	Sale	15.25	2,258	34,430	1,244,662	Feb 20 06:26 PM
Dubow Adam	General Counsel	Nov 16 '23	Sale	11.69	5,313	62,109	11,428	Nov 17 06:30 PM
Bender Jeremy	Chief Executive Officer	Nov 16 '23	Sale	11.69	3,107	36,321	709,429	Nov 17 06:20 PM
York Charles N II	COO, CFO and Secretary	Nov 16 '23	Sale	11.69	956	11,176	270,170	Nov 17 06:33 PM
Blackman Samuel C.	Head of Research and Developme	Nov 16 '23	Sale	11.69	709	8,288	1,238,234	Nov 17 06:26 PM
AI Day1 LLC	10% Owner	Oct 20 '23	Buy	9.97	111,387	1,110,907	12,929,322	Oct 20 04:02 PM
AI Day1 LLC	10% Owner	Oct 19 '23	Buy	10.06	384,400	3,867,372	12,817,935	Oct 20 04:02 PM
AI Day1 LLC	10% Owner	Oct 18 '23	Buy	10.21	979,667	10,000,049	12,433,535	Oct 20 04:02 PM
Bender Jeremy	Chief Executive Officer	Aug 17 '23	Sale	13.86	2,996	41,525	704,224	Aug 17 06:16 PM
York Charles N II	COO, CFO and Secretary	Aug 17 '23	Sale	13.86	922	12,779	267,501	Aug 17 07:02 PM
Blackman Samuel C.	Head of Research and Developme	Aug 17 '23	Sale	13.86	668	9,258	1,236,319	Aug 17 06:21 PM
AI Day1 LLC	10% Owner	Jun 09 '23	Buy	13.00	769,230	9,999,990	11,453,868	Jun 12 04:03 PM
Blackman Samuel C.	Chief Medical Officer	Jun 05 '23	Sale	16.00	1,229	19,664	1,234,363	Jun 07 04:51 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

KRRO

Korro Bio Inc.

DYN

Dyne Therapeutics Inc

DAWN

Day One Biopharmaceuticals Inc

Upgrade your FINVIZ experience